aod9604 clinical trials results weight loss BioWorld AOD 9604 Dosage Guide: Uses,

E.VisheM.TukachinskyH.ZhengS.-L.LiF.et al (2022)

You should contact your GP, call NHS 111, or seek urgent medical advice if you are currently using unlicensed peptides and experience any of the following: Severe or persistent nausea, vomiting, or abdominal pain Signs of infection at an injection site (redness, swelling, warmth, discharge) Unexplained changes in heart rate or palpitations Symptoms of an allergic reaction (rash, swelling, difficulty breathing) Persistent right upper quadrant pain, fever, or jaundice (which may indicate gallbladder problems) Significant unintentional weight loss or fatigue Call 999 or go to your nearest emergency department if symptoms are severe or rapidly worsening

Since 2000, 33 non-insulin peptide drugs have received approval worldwide

Groups with limited or no safety data Published human trials with AOD-9604 enrolled adults with obesity (BMI 30-45 kg/m^2), generally aged 18-65